[{"id":"31a2ef69-d213-4af8-a54e-135e260bb3b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04112810","created_at":"2021-01-18T20:06:28.002Z","updated_at":"2024-07-02T16:35:21.943Z","phase":"Phase 2","brief_title":"Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease","source_id_and_acronym":"NCT04112810","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ilumya (tildrakizumab-asmn)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-29"}]